Outcome of patients with chlorpyrifos intoxication
Introduction: There is a paucity of literature analyzing outcome of chlorpyrifos intoxication. Methods: A total of 40 patients with chlorpyrifos intoxication were seen at Chang Gung Memorial Hospital between 2008 and 2017. Patients were stratified into two subgroups according to their prognosis, as...
Gespeichert in:
Veröffentlicht in: | Human & experimental toxicology 2020-10, Vol.39 (10), p.1291-1300 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1300 |
---|---|
container_issue | 10 |
container_start_page | 1291 |
container_title | Human & experimental toxicology |
container_volume | 39 |
creator | Liu, H-F Ku, C-H Chang, S-S Chang, C-M Wang, I-K Yang, H-Y Weng, C-H Huang, W-H Hsu, C-W Yen, T-H |
description | Introduction:
There is a paucity of literature analyzing outcome of chlorpyrifos intoxication.
Methods:
A total of 40 patients with chlorpyrifos intoxication were seen at Chang Gung Memorial Hospital between 2008 and 2017. Patients were stratified into two subgroups according to their prognosis, as good (n = 12) or poor (n = 28). Good prognosis group were defined as patients who survived without serious complications, and poor prognosis group included patients who died and survived after development of severe complications. Demographic, clinical, laboratory, and mortality data were obtained for analysis.
Results:
Patients aged 53.8 ± 16.3 years and most were male (80.0%). All patients (100.0%) developed acute cholinergic crisis such as emesis (45.0%), respiratory failure (42.5%), tachycardia (30.0%), kidney injury (22.5%), and seizure (7.5%). Intermediate syndrome developed in 12.5% of patients, but none had delayed neuropathy (0%). The poor prognosis group suffered higher incidences of respiratory failure (p = 0.011), kidney injury (p = 0.026), and prolonged corrected QT interval (p = 0.000), and they had higher blood urea nitrogen level (p = 0.041), lower Glasgow coma scale score (p = 0.011), and lower monocyte count (p = 0.023) than good prognosis group. All patients were treated with atropine and pralidoxime therapy, but six patients (15.0%) still died of intoxication. In a multivariate logistic regression model, blood urea nitrogen was a significant risk factor for poor prognosis (odds ratio: 1.375, 95% confidence interval: 1.001–1.889, p = 0.049). Nevertheless, no mortality risk factor could be identified.
Conclusion:
The mortality rate of patients with chlorpyrifos intoxication was 15.0%. Furthermore, acute cholinergic crisis, intermediate syndrome, and delayed neuropathy developed in 100.0%, 12.5%, and 0% of patients, respectively. |
doi_str_mv | 10.1177/0960327120920911 |
format | Article |
fullrecord | <record><control><sourceid>proquest_AFRWT</sourceid><recordid>TN_cdi_proquest_journals_2429086529</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0960327120920911</sage_id><sourcerecordid>2429086529</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-12dddbd815f09f39b6560efacfd61aea28ece8527b7fd08767a224f391d2e143</originalsourceid><addsrcrecordid>eNp1kN1LwzAUxYMobk7ffZKCz9V7kyZpHmX4BYO97L2kTeI6tqYmLbr_3o5OBUG4cB_O75wDh5BrhDtEKe9BCWBUIgU1HOIJmWImZQoK2CmZHuT0oE_IRYwbABCK4zmZMMqYQM6nhC77rvI7m3iXtLqrbdPF5KPu1km13vrQ7kPtfEzqpvOfdTUAvrkkZ05vo706_hlZPT2u5i_pYvn8On9YpBUTvEuRGmNKkyN3oBxTpeACrNOVMwK11TS3lc05laV0BnIppKY0G0A01GLGZuR2jG2Df-9t7IqN70MzNBY0owpywakaKBipKvgYg3VFG-qdDvsCoThsVPzdaLDcHIP7cmfNj-F7lAFIRyDqN_vb-m_gF7jlbb8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2429086529</pqid></control><display><type>article</type><title>Outcome of patients with chlorpyrifos intoxication</title><source>Sage Journals GOLD Open Access 2024</source><creator>Liu, H-F ; Ku, C-H ; Chang, S-S ; Chang, C-M ; Wang, I-K ; Yang, H-Y ; Weng, C-H ; Huang, W-H ; Hsu, C-W ; Yen, T-H</creator><creatorcontrib>Liu, H-F ; Ku, C-H ; Chang, S-S ; Chang, C-M ; Wang, I-K ; Yang, H-Y ; Weng, C-H ; Huang, W-H ; Hsu, C-W ; Yen, T-H</creatorcontrib><description>Introduction:
There is a paucity of literature analyzing outcome of chlorpyrifos intoxication.
Methods:
A total of 40 patients with chlorpyrifos intoxication were seen at Chang Gung Memorial Hospital between 2008 and 2017. Patients were stratified into two subgroups according to their prognosis, as good (n = 12) or poor (n = 28). Good prognosis group were defined as patients who survived without serious complications, and poor prognosis group included patients who died and survived after development of severe complications. Demographic, clinical, laboratory, and mortality data were obtained for analysis.
Results:
Patients aged 53.8 ± 16.3 years and most were male (80.0%). All patients (100.0%) developed acute cholinergic crisis such as emesis (45.0%), respiratory failure (42.5%), tachycardia (30.0%), kidney injury (22.5%), and seizure (7.5%). Intermediate syndrome developed in 12.5% of patients, but none had delayed neuropathy (0%). The poor prognosis group suffered higher incidences of respiratory failure (p = 0.011), kidney injury (p = 0.026), and prolonged corrected QT interval (p = 0.000), and they had higher blood urea nitrogen level (p = 0.041), lower Glasgow coma scale score (p = 0.011), and lower monocyte count (p = 0.023) than good prognosis group. All patients were treated with atropine and pralidoxime therapy, but six patients (15.0%) still died of intoxication. In a multivariate logistic regression model, blood urea nitrogen was a significant risk factor for poor prognosis (odds ratio: 1.375, 95% confidence interval: 1.001–1.889, p = 0.049). Nevertheless, no mortality risk factor could be identified.
Conclusion:
The mortality rate of patients with chlorpyrifos intoxication was 15.0%. Furthermore, acute cholinergic crisis, intermediate syndrome, and delayed neuropathy developed in 100.0%, 12.5%, and 0% of patients, respectively.</description><identifier>ISSN: 0960-3271</identifier><identifier>EISSN: 1477-0903</identifier><identifier>DOI: 10.1177/0960327120920911</identifier><identifier>PMID: 32336155</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adult ; Aged ; Atropine ; Blood ; Chlorpyrifos ; Chlorpyrifos - toxicity ; Cholinergics ; Cholinesterase Inhibitors - toxicity ; Cholinesterase Reactivators - therapeutic use ; Coma ; Complications ; Confidence intervals ; Female ; Humans ; Insecticides - toxicity ; Intoxication ; Kidneys ; Male ; Middle Aged ; Monocytes ; Mortality ; Neuropathy ; Nitrogen ; Patients ; Pesticides ; Pralidoxime Compounds - therapeutic use ; Prognosis ; Regression analysis ; Regression models ; Renal failure ; Respiratory failure ; Retrospective Studies ; Risk analysis ; Risk factors ; Seizures ; Statistical analysis ; Subgroups ; Tachycardia ; Urea ; Vomiting</subject><ispartof>Human & experimental toxicology, 2020-10, Vol.39 (10), p.1291-1300</ispartof><rights>The Author(s) 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-12dddbd815f09f39b6560efacfd61aea28ece8527b7fd08767a224f391d2e143</citedby><cites>FETCH-LOGICAL-c365t-12dddbd815f09f39b6560efacfd61aea28ece8527b7fd08767a224f391d2e143</cites><orcidid>0000-0002-0907-1505</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/0960327120920911$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/0960327120920911$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21957,27844,27915,27916,44936,45324</link.rule.ids><linktorsrc>$$Uhttps://journals.sagepub.com/doi/full/10.1177/0960327120920911?utm_source=summon&utm_medium=discovery-provider$$EView_record_in_SAGE_Publications$$FView_record_in_$$GSAGE_Publications</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32336155$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, H-F</creatorcontrib><creatorcontrib>Ku, C-H</creatorcontrib><creatorcontrib>Chang, S-S</creatorcontrib><creatorcontrib>Chang, C-M</creatorcontrib><creatorcontrib>Wang, I-K</creatorcontrib><creatorcontrib>Yang, H-Y</creatorcontrib><creatorcontrib>Weng, C-H</creatorcontrib><creatorcontrib>Huang, W-H</creatorcontrib><creatorcontrib>Hsu, C-W</creatorcontrib><creatorcontrib>Yen, T-H</creatorcontrib><title>Outcome of patients with chlorpyrifos intoxication</title><title>Human & experimental toxicology</title><addtitle>Hum Exp Toxicol</addtitle><description>Introduction:
There is a paucity of literature analyzing outcome of chlorpyrifos intoxication.
Methods:
A total of 40 patients with chlorpyrifos intoxication were seen at Chang Gung Memorial Hospital between 2008 and 2017. Patients were stratified into two subgroups according to their prognosis, as good (n = 12) or poor (n = 28). Good prognosis group were defined as patients who survived without serious complications, and poor prognosis group included patients who died and survived after development of severe complications. Demographic, clinical, laboratory, and mortality data were obtained for analysis.
Results:
Patients aged 53.8 ± 16.3 years and most were male (80.0%). All patients (100.0%) developed acute cholinergic crisis such as emesis (45.0%), respiratory failure (42.5%), tachycardia (30.0%), kidney injury (22.5%), and seizure (7.5%). Intermediate syndrome developed in 12.5% of patients, but none had delayed neuropathy (0%). The poor prognosis group suffered higher incidences of respiratory failure (p = 0.011), kidney injury (p = 0.026), and prolonged corrected QT interval (p = 0.000), and they had higher blood urea nitrogen level (p = 0.041), lower Glasgow coma scale score (p = 0.011), and lower monocyte count (p = 0.023) than good prognosis group. All patients were treated with atropine and pralidoxime therapy, but six patients (15.0%) still died of intoxication. In a multivariate logistic regression model, blood urea nitrogen was a significant risk factor for poor prognosis (odds ratio: 1.375, 95% confidence interval: 1.001–1.889, p = 0.049). Nevertheless, no mortality risk factor could be identified.
Conclusion:
The mortality rate of patients with chlorpyrifos intoxication was 15.0%. Furthermore, acute cholinergic crisis, intermediate syndrome, and delayed neuropathy developed in 100.0%, 12.5%, and 0% of patients, respectively.</description><subject>Adult</subject><subject>Aged</subject><subject>Atropine</subject><subject>Blood</subject><subject>Chlorpyrifos</subject><subject>Chlorpyrifos - toxicity</subject><subject>Cholinergics</subject><subject>Cholinesterase Inhibitors - toxicity</subject><subject>Cholinesterase Reactivators - therapeutic use</subject><subject>Coma</subject><subject>Complications</subject><subject>Confidence intervals</subject><subject>Female</subject><subject>Humans</subject><subject>Insecticides - toxicity</subject><subject>Intoxication</subject><subject>Kidneys</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Monocytes</subject><subject>Mortality</subject><subject>Neuropathy</subject><subject>Nitrogen</subject><subject>Patients</subject><subject>Pesticides</subject><subject>Pralidoxime Compounds - therapeutic use</subject><subject>Prognosis</subject><subject>Regression analysis</subject><subject>Regression models</subject><subject>Renal failure</subject><subject>Respiratory failure</subject><subject>Retrospective Studies</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Seizures</subject><subject>Statistical analysis</subject><subject>Subgroups</subject><subject>Tachycardia</subject><subject>Urea</subject><subject>Vomiting</subject><issn>0960-3271</issn><issn>1477-0903</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kN1LwzAUxYMobk7ffZKCz9V7kyZpHmX4BYO97L2kTeI6tqYmLbr_3o5OBUG4cB_O75wDh5BrhDtEKe9BCWBUIgU1HOIJmWImZQoK2CmZHuT0oE_IRYwbABCK4zmZMMqYQM6nhC77rvI7m3iXtLqrbdPF5KPu1km13vrQ7kPtfEzqpvOfdTUAvrkkZ05vo706_hlZPT2u5i_pYvn8On9YpBUTvEuRGmNKkyN3oBxTpeACrNOVMwK11TS3lc05laV0BnIppKY0G0A01GLGZuR2jG2Df-9t7IqN70MzNBY0owpywakaKBipKvgYg3VFG-qdDvsCoThsVPzdaLDcHIP7cmfNj-F7lAFIRyDqN_vb-m_gF7jlbb8</recordid><startdate>202010</startdate><enddate>202010</enddate><creator>Liu, H-F</creator><creator>Ku, C-H</creator><creator>Chang, S-S</creator><creator>Chang, C-M</creator><creator>Wang, I-K</creator><creator>Yang, H-Y</creator><creator>Weng, C-H</creator><creator>Huang, W-H</creator><creator>Hsu, C-W</creator><creator>Yen, T-H</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7ST</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>SOI</scope><orcidid>https://orcid.org/0000-0002-0907-1505</orcidid></search><sort><creationdate>202010</creationdate><title>Outcome of patients with chlorpyrifos intoxication</title><author>Liu, H-F ; Ku, C-H ; Chang, S-S ; Chang, C-M ; Wang, I-K ; Yang, H-Y ; Weng, C-H ; Huang, W-H ; Hsu, C-W ; Yen, T-H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-12dddbd815f09f39b6560efacfd61aea28ece8527b7fd08767a224f391d2e143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Atropine</topic><topic>Blood</topic><topic>Chlorpyrifos</topic><topic>Chlorpyrifos - toxicity</topic><topic>Cholinergics</topic><topic>Cholinesterase Inhibitors - toxicity</topic><topic>Cholinesterase Reactivators - therapeutic use</topic><topic>Coma</topic><topic>Complications</topic><topic>Confidence intervals</topic><topic>Female</topic><topic>Humans</topic><topic>Insecticides - toxicity</topic><topic>Intoxication</topic><topic>Kidneys</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Monocytes</topic><topic>Mortality</topic><topic>Neuropathy</topic><topic>Nitrogen</topic><topic>Patients</topic><topic>Pesticides</topic><topic>Pralidoxime Compounds - therapeutic use</topic><topic>Prognosis</topic><topic>Regression analysis</topic><topic>Regression models</topic><topic>Renal failure</topic><topic>Respiratory failure</topic><topic>Retrospective Studies</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Seizures</topic><topic>Statistical analysis</topic><topic>Subgroups</topic><topic>Tachycardia</topic><topic>Urea</topic><topic>Vomiting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, H-F</creatorcontrib><creatorcontrib>Ku, C-H</creatorcontrib><creatorcontrib>Chang, S-S</creatorcontrib><creatorcontrib>Chang, C-M</creatorcontrib><creatorcontrib>Wang, I-K</creatorcontrib><creatorcontrib>Yang, H-Y</creatorcontrib><creatorcontrib>Weng, C-H</creatorcontrib><creatorcontrib>Huang, W-H</creatorcontrib><creatorcontrib>Hsu, C-W</creatorcontrib><creatorcontrib>Yen, T-H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Environment Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Environment Abstracts</collection><jtitle>Human & experimental toxicology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Liu, H-F</au><au>Ku, C-H</au><au>Chang, S-S</au><au>Chang, C-M</au><au>Wang, I-K</au><au>Yang, H-Y</au><au>Weng, C-H</au><au>Huang, W-H</au><au>Hsu, C-W</au><au>Yen, T-H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcome of patients with chlorpyrifos intoxication</atitle><jtitle>Human & experimental toxicology</jtitle><addtitle>Hum Exp Toxicol</addtitle><date>2020-10</date><risdate>2020</risdate><volume>39</volume><issue>10</issue><spage>1291</spage><epage>1300</epage><pages>1291-1300</pages><issn>0960-3271</issn><eissn>1477-0903</eissn><abstract>Introduction:
There is a paucity of literature analyzing outcome of chlorpyrifos intoxication.
Methods:
A total of 40 patients with chlorpyrifos intoxication were seen at Chang Gung Memorial Hospital between 2008 and 2017. Patients were stratified into two subgroups according to their prognosis, as good (n = 12) or poor (n = 28). Good prognosis group were defined as patients who survived without serious complications, and poor prognosis group included patients who died and survived after development of severe complications. Demographic, clinical, laboratory, and mortality data were obtained for analysis.
Results:
Patients aged 53.8 ± 16.3 years and most were male (80.0%). All patients (100.0%) developed acute cholinergic crisis such as emesis (45.0%), respiratory failure (42.5%), tachycardia (30.0%), kidney injury (22.5%), and seizure (7.5%). Intermediate syndrome developed in 12.5% of patients, but none had delayed neuropathy (0%). The poor prognosis group suffered higher incidences of respiratory failure (p = 0.011), kidney injury (p = 0.026), and prolonged corrected QT interval (p = 0.000), and they had higher blood urea nitrogen level (p = 0.041), lower Glasgow coma scale score (p = 0.011), and lower monocyte count (p = 0.023) than good prognosis group. All patients were treated with atropine and pralidoxime therapy, but six patients (15.0%) still died of intoxication. In a multivariate logistic regression model, blood urea nitrogen was a significant risk factor for poor prognosis (odds ratio: 1.375, 95% confidence interval: 1.001–1.889, p = 0.049). Nevertheless, no mortality risk factor could be identified.
Conclusion:
The mortality rate of patients with chlorpyrifos intoxication was 15.0%. Furthermore, acute cholinergic crisis, intermediate syndrome, and delayed neuropathy developed in 100.0%, 12.5%, and 0% of patients, respectively.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>32336155</pmid><doi>10.1177/0960327120920911</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-0907-1505</orcidid></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | ISSN: 0960-3271 |
ispartof | Human & experimental toxicology, 2020-10, Vol.39 (10), p.1291-1300 |
issn | 0960-3271 1477-0903 |
language | eng |
recordid | cdi_proquest_journals_2429086529 |
source | Sage Journals GOLD Open Access 2024 |
subjects | Adult Aged Atropine Blood Chlorpyrifos Chlorpyrifos - toxicity Cholinergics Cholinesterase Inhibitors - toxicity Cholinesterase Reactivators - therapeutic use Coma Complications Confidence intervals Female Humans Insecticides - toxicity Intoxication Kidneys Male Middle Aged Monocytes Mortality Neuropathy Nitrogen Patients Pesticides Pralidoxime Compounds - therapeutic use Prognosis Regression analysis Regression models Renal failure Respiratory failure Retrospective Studies Risk analysis Risk factors Seizures Statistical analysis Subgroups Tachycardia Urea Vomiting |
title | Outcome of patients with chlorpyrifos intoxication |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T21%3A17%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_AFRWT&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcome%20of%20patients%20with%20chlorpyrifos%20intoxication&rft.jtitle=Human%20&%20experimental%20toxicology&rft.au=Liu,%20H-F&rft.date=2020-10&rft.volume=39&rft.issue=10&rft.spage=1291&rft.epage=1300&rft.pages=1291-1300&rft.issn=0960-3271&rft.eissn=1477-0903&rft_id=info:doi/10.1177/0960327120920911&rft_dat=%3Cproquest_AFRWT%3E2429086529%3C/proquest_AFRWT%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2429086529&rft_id=info:pmid/32336155&rft_sage_id=10.1177_0960327120920911&rfr_iscdi=true |